Cargando…

Risk Factors of Biochemical Failure in Locally Advanced Carcinoma Prostate Treated With Definitive External Beam Radiotherapy and Androgen Deprivation Therapy: Experience From Tertiary Care Center in North India

Background Locally advanced prostate cancer (LACAP), despite external beam radiotherapy (EBRT) along with antiandrogen therapy (ADT) has risk of prostate-specific antigen (PSA) progression. Furthermore, number of studies have emphasized on different prognostic factors. The purpose of our study is to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sidhu, Manjinder, Paul, Davinder, Sood, Sandhya, Jain, Kunal, Singh, Jagdeep, Aggarwal, Ritu, Sood, Divyaanshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412057/ https://www.ncbi.nlm.nih.gov/pubmed/34513468 http://dx.doi.org/10.7759/cureus.16895

Ejemplares similares

Analysis of Rapid arc-based Radiation Therapy on Dosimetric Parameters in Cervical Cancer Patients with and without Bone Marrow Sparing
por: Aggarwal, Ritu, et al.
Publicado: (2022)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
por: Ohashi, Toshio, et al.
Publicado: (2014)

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
por: Parker, C C, et al.
Publicado: (2002)

Biochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
por: Rakhsha, Afshin, et al.
Publicado: (2015)

Treatment of Acute Leukemia During COVID-19: Focused Review of Evidence
por: Singh, Suvir, et al.
Publicado: (2021)

Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
por: Kim, Yeon Joo, et al.
Publicado: (2020)

Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
por: Heesterman, Berdine L., et al.
Publicado: (2023)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
por: Utsumi, Takanobu, et al.
Publicado: (2023)

Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy
por: Erlandsson, Ann, et al.
Publicado: (2023)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Significant impact of biochemical recurrence on overall mortality in patients with high‐risk prostate cancer after carbon‐ion radiotherapy combined with androgen deprivation therapy
por: Kasuya, Goro, et al.
Publicado: (2016)

Salvage Radiotherapy Plus Androgen Deprivation Therapy for High-Risk Prostate Cancer with Biochemical Failure after High-Intensity Focused Ultrasound as Primary Treatment
por: Huang, Ying-Che, et al.
Publicado: (2022)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Can androgen-deprivation therapy obviate the need of channel transurethral resection of the prostate in advanced prostate cancer with urinary retention? A prospective study
por: Sood, Rajeev, et al.
Publicado: (2017)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study
por: Wu, Jun-Xin, et al.
Publicado: (2016)

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
por: Sanguineti, G, et al.
Publicado: (2002)

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer
por: Milecki, Piotr, et al.
Publicado: (2009)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Primary Extranodal Non-Hodgkin Lymphomas: A First Tertiary Care Experience from Punjab, North India
por: Narang, Vikram, et al.
Publicado: (2020)

Using a Further Planning MRI after Neoadjuvant Androgen Deprivation Therapy Significantly Reduces the Radiation Exposure of Organs at Risk in External Beam Radiotherapy of Prostate Cancer
por: Merten, Roland, et al.
Publicado: (2023)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Role of Perfusion CT Differentiating Hemangiomas from Malignant Hepatic Lesions
por: Singh, Jagjeet, et al.
Publicado: (2014)

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy
por: Liu, Qiuli, et al.
Publicado: (2018)

Cancer-related fatigue during combined treatment of androgen deprivation therapy and radiotherapy is associated with mitochondrial dysfunction
por: Feng, Li Rebekah, et al.
Publicado: (2020)

Cancer-related fatigue during combined treatment of androgen deprivation therapy and radiotherapy is associated with mitochondrial dysfunction
por: Feng, Li Rebekah, et al.
Publicado: (2020)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
por: Björeland, Ulrika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d5g8fq6hq6kfl8cg0g3l37mkjh